India's Future as a Biologics Manufacturing Hub - Collaborations between Western and Indian companies may provide the best path for offshoring successfully and for developing India's readiness. - BioP

ADVERTISEMENT

India's Future as a Biologics Manufacturing Hub
Collaborations between Western and Indian companies may provide the best path for offshoring successfully and for developing India's readiness.


BioPharm International
Volume 23, Issue 3


Karen Politis Virk
India has long been an important producer of small-molecule active pharmaceutical ingredients (APIs) for Western pharmaceutical companies, particularly in the generics sector. In fact, India currently accounts for approximately 8% of all global pharmaceutical production, and India's contract manufacturing market is growing more than three times the rate of the global contract market, according to a new survey conducted jointly by the Organization of Pharmaceutical Producers of India and Ernst & Young analysts.1


Ongoing Concerns about Offshoring to India
Now, as the biopharmaceutical sector continues to grow, many wonder whether India can take a similar role in the biologics arena. Key questions, however, surround India's regulatory oversight, intellectual property protection, and compliance with current good manufacturing practices (cGMPs) (see box). Furthermore, recent high-profile problems with India's small-molecule manufacturing, such as the US Food and Drug Administration's September 2008 ban on imports from two Ranbaxy sites, because of consistent failure to comply with cGMPs, heighten concerns about quality.

Yet the increasing importance of biologics makes the eventual offshoring of biologics manufacturing to India seem a likely path. Biologics are expected to account for almost 50% of all approved new pharmaceuticals by 2010.2 Yet biologics also have tended to be very costly, and it is expected that biosimilars will become increasingly important in the West, as Europe's biosimilars market grows and especially once legislation is passed to create a regulatory pathway for biosimilars in the US. The biosimilars market is likely to offer India the greatest opportunity for manufacturing biologics for the West.

COLLABORATION BETWEEN WESTERN AND INDIAN COMPANIES

One way that some Western companies are seeking to take advantage of the cost advantages of offshoring to India while reducing risk is through collaborations.

For example, the Swiss-based contract manufacturing organization (CMO) Lonza, has recently announced plans to invest in two major projects in the Genome Valley outside of Hyderabad—India's first state-of-the-art biotech complex for life science research, training, and manufacturing. Lonza's investment, which is scheduled to begin in 2011, is expected to take place in two phases. Both phases will include expanding manufacturing capabilities as well as biologics research and development.3 Another example is the Indian CMO, Kemwell, which recently announced plans to build a new biopharmaceutical manufacturing plant in Bangalore, in collaboration with the German company Boehringer Ingelheim (BI).4

Lonza and BI together hold over half of the market for outsourced protein APIs.5 The decision by Lonza and BI to make these important investments in manufacturing facilities to India reflects the West's changing view on offshoring biologics to India and will facilitate future collaborations between Indian manufacturing companies and other multinationals.

Western CMOs are not the only ones investing in India, of course. For example, Mumbai-based Reliance Life Sciences, which started off in 2001 developing stem cell products and expanded into biopharmaceuticals in 2006, set up a collaboration in 2007 with GeneMedix, a UK company with a pipeline of biosimilars.5

Other Indian biotech firms, meanwhile, are developing biologics based upon technology transferred from abroad. For example, Bharat Biotech International (Hyderabad) and the Serum Institute of India (Pune) have licensed various vaccine technologies from institutions in Canada, the United States, and the Netherlands. Bharat Biotech International is the first vaccine manufacturer in a developing country to produce a foreign proprietary product, i.e., Wyeth's (now Pfizer's) Haemophilus influenzae B (Hib) vaccine.9


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here